An observational study in Seizures, Seizure Disorder and Seizure Newborn, sponsored by Children's Hospital of Fudan University. Recruiting at 1 site in China. Open to participants aged Up to 12 Months. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Children's Hospital of Fudan University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Seizures with a site in China — 14 open to participants now, 16 under way, 9 of them phase 3. Seizures · China.
Among the 39 studies in Seizures with a site in China, this one is the 2nd largest by planned enrollment of the 13 observational ones that give a count, is the only one that started in 2016, is one of 13 observational ones, reaches primary completion later than 6 of the 15 other live ones, and was the 15th registered.
766 studies on the registry are indexed under Seizures; 133 are open to participants now.
Browse Seizures studies →14 of the 39 studies in Seizures with a site in China are open now. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Epygenix · Sites in China, United States, Hungary and 7 more countries
Ages 2–55
UCB Biopharma SRL · Sites in China, United States, Australia and 10 more countries
Ages 12+
Wei Zhao · Sites in China
Ages 65–100
Epygenix · Sites in China, United States, Argentina and 8 more countries
Ages 2+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 92 Seizures studies recruiting now, 36 (39%) set no upper age limit and 43 (47%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: Up to 12 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 19
First in 2006; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 140 across 216 observational studies indexed under Seizures.
Median enrollment 280 across the 26 interventional studies, 500 across the 13 observational. Of the 17 that completed or were terminated, 11 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 39 have an industry lead sponsor. The 10 most frequent:
Children's Hospital of Fudan University is the lead sponsor of 268 studies on the registry; 94 are open to participants now.
Children's Hospital of Fudan University has 6 studies filed under Seizures — fewer than ten, so there is no comparison to draw.
7 of the studies in Seizures with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT07239115Phase 3Beijing Tiantan HospitalLevetiracetam for Seizure Prevention After Brain Tumor Surgery | 2027-01 |
| NCT05077904Phase 3UCB Biopharma SRLA Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures | 2027-03-29 |
| NCT04462770Phase 3EpygenixA Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | 2027-04 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
Add all 7 to your calendar (.ics) → With an account.
Among the 39 studies in Seizures with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Genetic diagnosis for neonates suffering from epilepsy has important implications for treatment, prognosis, and development of precision medicine strategies. Investigator performed exome sequencing (ES) or targeted sequencing on neonates with seizure onset within the first month of life. Investigator subgrouped our patients based on the onset age of seizure into neonatal and before 1 year (1-12 months), to compare the clinical and genetic features and treatment strategies.
Seizure is one of the most common neurological conditions in neonates, and has substantial impact on patients'quality of life and social integration. Epileptic encephalopathy is characterized by refractory seizures, cognitive dysfunction, and poor prognosis. Despite the recent progress in technology, molecular diagnosis of neonates suffering from possible epileptic seizures can be challenging, due to genetic and phenotypic heterogeneities. A large number of specific pathogenic variations have been related to various forms of epilepsies. Next-generation sequencing (NGS) has significantly improved the molecular diagnosis for rare diseases. NGS focusing on genes known to be associated with human diseases is a practical approach as a first-tier assessment for patients with heterogeneous genetic background. In addition, currently medical therapy for seizure is not based on the etiology, but the clinical manifestations, and the main purpose is not to rescue the underlying diseases process, but just to reduce the likelihood of seizures occurrence. In this study, Investigator performed NGS on neonates with seizure onset before 1 year of age, to detect and quantify genetic variants, and assess existing therapeutic effects. Our findings will have important implications for the development of precision medicine strategies.
The subjects were treated in the Department of Neonatology of Children Hospital of Fudan University. All samples in this study were collected with appropriate informed consent and approval of the ethics committee of Children's Hospital, Fudan University. The methods used in this study were carried out in accordance with the approved guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Mutation rate of common seizure genes
We'll get the genetic profiles of all neonates who had seizures during this period. The mutation rate of common variant gene was calculated by gene spectrum.
Time frame: From the oneset of seizure to the genetic sequencing finish, the process may last up to 3 months.
Rate of seizure free
After the onset of seizure, through clinical management and individualized intervention, we expect to observe the number and proportion of effective seizure treatments.
Time frame: From the onset of seizure to 6 months after the onset of seizure
Started Aug 2016 (actual). Primary completion is estimated for Dec 2026, 124 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital of Fudan University →